Dr. O’Regan on the SOFT Trial in Premenopausal Women With HR+ Breast Cancer
January 12th 2023Ruth M. O’Regan, MD, discusses the significance of the Breast Cancer Index as a prognostic tool, as well as the investigation of the phase 3 SOFT trial for patients with early-stage, hormone receptor-positive breast cancer.
Read More
Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer
May 16th 2017Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.
Read More
Dr. O'Regan Discusses BELLE-3 Study in Breast Cancer
January 7th 2017Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment and were treated with an aromatase inhibitor.
Read More
Dr. O'Regan Discusses Breast Cancer Index in HER2-Positive/HR-Positive Patients
June 17th 2015Ruth O'Regan, MD, medical oncology, Breast Cancer Clinic, University of Wisconsin Carbone Cancer Center, faculty, University of Wisconsin School of Medicine and Public Health, evaluates the Breast Cancer Index in patients with HER2-positive, HR-positive breast cancer for risk of late recurrence and endocrine benefit.
Read More
Dr. O'Regan Discusses Updates in HER2-Positive Breast Cancer
August 14th 2014Ruth M. O'Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.
Read More
Dr. O'Regan on Breast Cancer Endocrine Therapy Resistance
January 8th 2014Ruth M. O'Regan, MD, director of Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses resistance to endocrine therapy in patients with metastatic, hormone receptor-positive breast cancer.
Read More